EP 0956046 A4 20041020 - CELLULAR VACCINES AND IMMUNOTHERAPEUTICS AND METHODS FOR THEIR PREPARATION
Title (en)
CELLULAR VACCINES AND IMMUNOTHERAPEUTICS AND METHODS FOR THEIR PREPARATION
Title (de)
ZELLULÄRE IMPFSTOFFE UND IMMUNTHERAPEUTIKA SOWIE VERFAHREN ZU DEREN HERSTELLUNG
Title (fr)
VACCINS CELLULAIRES IMMUNOTHERAPEUTIQUES ET LEURS PROCEDES DE PREPARATION
Publication
Application
Priority
- US 9710238 W 19970611
- US 1963996 P 19960612
Abstract (en)
[origin: WO9747271A2] The present invention provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic cells, resulting in a cellular vaccine that can stimulate T cell activation, which in turn leads to an effective immune response. The cellular vaccines of the present invention are useful for the prevention and treatment of diseases which develop and/or persist by escaping the immune response triggered by T cell activation. Such diseases include, for example, all cancers, natural and induced immune deficiency states, and diseases caused by infections with a variety of pathogens.
IPC 1-7
A61K 39/395; A01N 63/00; C12N 5/00; C07K 16/00; C07K 16/28; C07K 16/30
IPC 8 full level
A61K 38/00 (2006.01); A61K 31/00 (2006.01); A61K 35/12 (2006.01); A61K 35/13 (2015.01); A61K 35/14 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 31/00 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP US)
A61K 35/13 (2013.01 - EP); A61K 39/001116 (2018.08 - EP US); A61P 31/00 (2018.01 - EP); A61P 31/14 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 31/20 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 35/02 (2018.01 - EP); C07K 16/2818 (2013.01 - EP); C07K 16/2878 (2013.01 - EP); A61K 2039/5152 (2013.01 - EP)
C-Set (source: EP)
Citation (search report)
- [X] EP 0610046 A2 19940810 - BRISTOL MYERS SQUIBB CO [US]
- [X] SAHIN U ET AL: "Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. JAN 1996, vol. 42, no. 1, January 1996 (1996-01-01), pages 9 - 14, XP002293245, ISSN: 0340-7004
- [A] MACLEAN JAMES A ET AL: "Anti-CD3: Anti-IL-2 receptor bispecific monoclonal antibody: Targeting of activated T cells in vitro", JOURNAL OF IMMUNOLOGY, vol. 150, no. 4, 1993, pages 1619 - 1628, XP002156055, ISSN: 0022-1767
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9747271 A2 19971218; WO 9747271 A3 19980212; AU 4228397 A 19980107; AU 727955 B2 20010104; CA 2258082 A1 19971218; CN 1221349 A 19990630; EP 0956046 A2 19991117; EP 0956046 A4 20041020; JP 3676380 B2 20050727; JP H11514666 A 19991214
DOCDB simple family (application)
US 9710238 W 19970611; AU 4228397 A 19970611; CA 2258082 A 19970611; CN 97195438 A 19970611; EP 97940524 A 19970611; JP 50183398 A 19970611